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HEADACHE: THE PLACEBO EFFECTS IN THE CONTROL
GROUPS IN RANDOMIZED CLINICAL TRIALS; AN ANALYSIS OF
SYSTEMATIC REVIEWS
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doi:10.1016/j.ABSTRACTObjective: The purpose of this study is to describe the effects in the placebo and “no treatment” arms in trials with
headache patients.
Method: This is a secondary analysis of randomized controlled trials from 8 systematic reviews and selected trials
with a “no treatment” or placebo control group. The different types of “no treatment” and placebo interventions were
assessed and classified into 6 subgroups. The analyses were carried out according to type of outcome variable.
Results: In total, 119 studies were included (7119 participants). The mean recovery rate in all control groups was
35.7%. Significantly more participants recovered in control groups of pharmacological studies than in
nonpharmacological studies: 38.5% vs 15.0%, respectively. Adults were more likely to recover in nonpharmacological
studies and children in pharmacological studies.
Conclusions: The mean recovery rate in the control groups was 36%. The recovery rate varied substantially between
type of intervention and patients. (J Manipulative Physiol Ther 2011;34:297-305)
Key Indexing Terms: Headache; Placebo Effect; Randomized Control TrialHeadache is a frequently heard complaint in generalpractice.1 The lifetime prevalence of headache inwomen and men is 95% and 90%, respectively.1
Two of the most common types of headache are tension-
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.has a 1-year prevalence of 63% in the general population,1
and migraine has a prevalence of 0.5% to 13.6% in children
and adolescents.2 In adults, the 1-year prevalence of
migraine is 17% in women and 6% in men.3 The prevalence
increases by age; most cases start before the age of 20
years,2 although 23% of the children were migraine free
before the age of 25 years, and around the age of 50 years,
more than half of the migraine group still had migraine
attacks.4 Headache has a high socioeconomic impact, and it
greatly influences quality of life.5,6 Because of the
symptoms, daily activities, family, work, and social
contacts can be disturbed.6
There are many studies describing the effect of treatment
in patients with migraine and TTH. Treatment can consist
of pharmacological or nonpharmacological interventions.
Pharmacological treatments can be divided into acute or
prophylactic medications; nonpharmacological treatments
are mostly behavioral interventions like relaxation therapy,
cognitive therapy, electromyographic (EMG) biofeedback,
or physiotherapy.
The criterion standard to investigate the efficacy of
medication or other therapies is a randomized controlled
trial (RCT). Different kinds of control groups are used in
these studies. Placebo controls are often used in297
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or pseudobehavioral interventions are often used in
behavioral trials. The placebo and “no treatment” in-
terventions intend to be less or ineffective because the
specific effective element of the treatment has been
removed. In most studies, the participants in both the
active and “no treatment” or placebo groups tend to recover
to some extent. This phenomenon can also be seen in
patients with a chronic disease, like headache.7,8 Research
suggests that this effect is stronger for children than for
adults.8 These publications described the response in
migraine trials; however, there is little evidence supporting
such outcome in TTH patients.
The question remains whether the degree of recovery
depends on the type of “no treatment” and/or placebo
intervention in the control group. Although the intention
of control interventions is to be relatively ineffective,
the question rises as to what kinds of determinants
might cause the improvement seen in these groups. The
aim of this study was to describe and compare the
observed effects, often called placebo effects, in the “no
treatment” and placebo control groups in RCTs with
TTH patients (adults and children) and children or
adolescents with migraine.METHODS
Design
This study was a secondary analysis of randomized
clinical trials in an existing database of systematic reviews.Study Selection
A data set of 8 recent (2004-2010) systematic reviews on
patients with TTH (adults and children) and migraine (only
children and adolescents) was used, which included 197
original studies.9-16 From this data set, RCTs with a “no
treatment” or placebo control group were selected for
review. Studies with missing data on the outcome measures
were excluded.
The control groups included placebo medication,
pseudobehavioral treatments, WLCs, and “no treatment”
controls. Two authors (FG and AVB) screened the studies
for inclusion. Disagreements on eligibility were solved by
consensus or with a third author (AV).Risk of Bias
The original review authors assessed and scored the
methodological quality of the RCTs according to the
Delphi list.17 The score from the original extraction forms
is used; see the original reviews for the specific items with
positive scores.9-16Data Extraction
Two review authors (FG and AVB) each performed data
extraction for half of the RCTs and checked the data
extraction for the other half. Consensus was reached in case
of disagreement. The extracted information consisted of
demographical data (age, sex), detailed description of the
content of the control groups (number of participants and
dropouts, intervention type, study design, duration of the
intervention), results of the control groups on the relevant
outcome measures, and the adverse events. The relevant
outcome values were proportion of participants recovered,
headache intensity, frequency and duration, pain free,
headache index, rescue medication, and adverse events.Data Analysis
Based on the data presented in the original RCTs, the
relative improvement (percentage) is calculated from
baseline until posttreatment and from baseline until
follow-up (if stated), only for the “no treatment” and
placebo control groups. Furthermore, the proportion of
recovered participants is calculated. Not every study
reported all the outcome measures previously described.
Therefore, our analysis is based on the data available in the
included studies.
The control groups are split into 6 subgroups
according to the intervention under study: Pharmacolog-
ical trials were classified into (1) acute or (2) prophylactic
placebo medication. Nonpharmacological trials were
classified into (3) WLC groups; (4) pseudo-EMG
biofeedback, pseudorelaxation, and pseudoacupuncture;
(5) attention placebo control and discussion/information
groups; and 6) “others.”
Furthermore, differences in recovery were analyzed
between adults and children, parallel and crossover designs,
and TTH and migraine. We assumed the outcome values to
be normally distributed. Box plots were made to visualize
the distribution of the different outcome values (weighted
for sample size). Next, mean values and corresponding 95%
confidence interval (CI) were calculated for different
subgroups. To test for significant differences in responses
between the 4 nonpharmacological subgroups, a 1-way
analysis of variance with post hoc analysis was used. All the
other comparisons were between 2 subgroups; so for these
comparisons, an unpaired t test was used. A linear
regression analysis was used to correct for confounders.RESULTS
Data Set
Of the 197 RCTs from the original reviews, 131 had a
“no treatment” or placebo control group (the list of studies
is available upon request from the corresponding author).
The remaining studies had control groups consisting of
other medications or therapies (pragmatic trials). Eleven
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for the “no treatment” or placebo control groups, and one
other study had none of our selected relevant outcome
measures. In total, 119 RCTs (85 on TTH and 34 on
migraine) were included in our analysis (Fig 1), with a total
of 7119 participants (5913 diagnosed with TTH and 1206
with migraine) in 131 “no treatment” or placebo control
groups. The number of participants per group ranged from 4
to 447, with a mean of 54.3.Fig 1. Flowchart.Risk of Bias
The mean quality score of studies with a “no treatment”
or placebo control group was 4.5 out of 10, compared with
the mean quality score of 4.2 of the original data set. Overall,
42 studies (35.3%) were considered to be of high quality (or
low risk of bias); 35 of these were pharmacological studies,
and 7 were nonpharmacological studies.9-11,13-16InterventionsPharmacological Controls. In pharmacological studies, 34
placebo control groups (n = 1017 participants) were found
on prophylactic medication9,11,12,15 and 44 placebo control
groups (n = 5369) on acute medication.10,11,13 In 57.7% of
these 78 control groups, the placebo was described as
“identical in shape or color” or “matching”; in 6.4%, the
placebo was identical and had the same taste. In the
remaining 35.9%, no specific description besides the word
placebo was given.
Nonpharmacological Controls. In the nonpharmacological
studies 53 “no treatment” control groups were found
with a total of 733 participants. These were classified into
4 subgroups:
Waiting List Controls. In total, there were 20 control
groups including a WLC (n = 279).11,12,14,16 Participants in
these studies were placed on a waiting list. In most of the
cases, they were told that the treatment groups were
temporarily filled and the treatment would start within 2 to
12 weeks. During this time, they had to fill in the headache
diaries similar to the participants in the intervention group.
Pseudo-EMG Feedback, pseudoacupuncture, or pseudo-
relaxation. In total, there were 13 control groups (n = 133)
that received a treatment designed to be consistent with
the therapy in the active treatment groups, but without the
specific active elements of the treatment.9,11,12,14,16 This
enabled the researchers to control also for attention,
expectations of improvement, information, contact with the
investigator, andmedical equipment. There were many forms
of pseudo-EMGbiofeedback. For instance, in some cases, the
tone heard by the participants was not consistent with their
tension level because it was previously recorded. They
received no specific instructions, but had to reduce the level oftension by themselves, or were told that the tone would help
them to relax by keeping out intruding thoughts.9,11 In other
cases, EMG was measured; but no feedback tone was given.
Participants received instructions to relax or discuss their
headache.11,12 In one other study, participants received
pseudoacupuncture during which the needles were inserted
in the stratum corneum instead of the dermis.14
Attention Placebo or Discussion Groups. In total, 11
control groups (n = 194) were designed as attention
placebo or discussion groups.11,12,14 They mainly con-
trolled for attention and time to be comparable with the
intervention. In most studies, they received information on
causes of headache and common triggers. They discussed
psychological conflicts and stressful situations. In some
cases, they received general or somewhat specific advice
for coping skills.12,14 In all the other cases, they received
no advice.11,12,14
“Others.” In total, 10 control groups (n = 127) were
classified as “others.”11,12,14,16 In most of these studies, no
treatment was given, nor were they placed on a waiting
list. They had to self monitor through a headache
diary.12,14 In 3 studies, participants had to lie still for a
certain amount of time. One study could not be placed in
one of the former groups. In this study, participants were
placed on a waiting list and received a pseudo-EMG
measurement without feedback.11Outcome Measures
There was some variation between the different
definitions of recovery. Most often, it was defined by the
original study authors as 50% or more improvement of the
complaints posttreatment or 50% or more improvement on
the headache index. The definition of recovery as it was
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11-point scales or visual analogue scales. Headache
frequency and duration were also scored on different time
units or point scales. A headache index was most often
calculated as a product or sum of the headache frequency,
duration, and intensity; but there were some variations.
Some studies registered if participants rated themselves as
being pain free. Frequently, this was measured as the
proportion of participants that were pain free 2 hours after
administration of the study medication. Rescue medication
was measured as the proportion of participants that used
analgesics if the study medication did not work, mostly
within 2 hours after administration of the study drug.
Adverse events were frequently measured. Sometimes,
studies reported the number of participants with an adverse
event; and in other cases, they reported the number of
adverse events (which could be more than 1 per patient).
We only used the number of participants as result.Fig 3. Box plot showing the difference in recovered participants
between acute and prophylactic placebo, weighted by sample size
(Color version of figure is available online.)Recovery in the Control Groups
Overall, the mean recovery rate in the control groups was
35.7% (95% CI, 35.0-36.4).
Pharmacological Studies. In pharmacological studies, an
average of 38.5% (95% CI, 37.8-39.3) of the participants in
the control groups recovered and 21.8% (95% CI, 21.3-22.4)
of the participants were pain free 2 hours after administration
of the placebomedication. Themean use of rescuemedication
was 33.2% (95% CI, 32.4-33.9), and 12.7% (95% CI,
12.4-13) of the participants experienced adverse events
(Fig 2). Most adverse events were minor complaints like
tiredness, drymouth, dizziness, or gastrointestinal complaints.
When the acute and prophylactic studies were separated,
recovery was significantly higher in participants who used
acute placebo medication (39.6%; 95% CI, 38.8-40.4) vs
participants using prophylactic placebo medication (32.8%;
95% CI, 30.9-34.6) (Fig 3). The reduction in headache
intensity was also significantly higher in the acute placebo
group. Participants in the prophylactic control groups
experienced significantly more adverse events than partic-
ipants in the acute placebo group: 22.6% (95% CI, 20.8-
24.3) vs 11.4% (95% CI, 11.1-11.6), respectively.
Nonpharmacological Studies. On average, 15.0% (95% CI,
13.5-16.6) of the participants recovered in the control
groups of nonpharmacological studies. An improvement
was found for headache intensity, frequency, and duration
of 10.3% (95% CI, −12.3 to −8.3), 14.0% (95% CI, −15.9
to −12.0), and 9.7% (95% CI, −11.8 to −7.7), respectively.
Evaluating the difference in recovery between the 4
different types of control groups, a mean recovery rate was
found in the WLC group of 17.9% (95% CI, 15.3-20.6);
8.4% (95% CI, 6.3-10.5) for the pseudobehavioral in-
terventions; 18.3% (95% CI, 15.7-20.9) for the attention
placebo groups; and 6.4% (95% CI, 3.8-9.0) for the “others”
(Fig 4). Recovery rates were significantly higher in the.WLC and attention placebo groups vs the “others” and the
pseudobehavioral treatments.Pharmacological vs Nonpharmacological Interventions. The differ-
ence between the proportions of recovered participants in
the control groups of pharmacological control groups
(38.5%; 95% CI, 37.8-39.3) compared with the nonphar-
macological control groups (15.0%; 95% CI, 13.5-16.6) is
significant in favor of the pharmacological studies (Fig 5).
This is also the case for the improvement in headache
intensity, frequency, duration, and headache index, respec-
tively. When the recovery rates were corrected for the
quality scores of the studies, the difference between these
groups became smaller, but was still significant.Adults vs Children. No significant difference in recovery
rates was found between adults and children in the total
study population; but after correction for quality score, the
difference in recovery rates became significant, although
still small (35.4% in adults vs 37.7% in children).
When the control groups were split into pharmacolog-
ical and nonpharmacological groups, adults were slightly
more likely to recover in nonpharmacological studies:
17.7% (95% CI, 14.6-20.8) vs 14.1% (95% CI, 12.3-15.9)
in children. In pharmacological studies, significantly more
children recovered (also after correction for the quality
score): 45.1% (95% CI, 44.0-46.2) of the children vs
36.5% (95% CI, 35.7-37.4) of the adults (Fig 6). After
Fig 5. Box plot showing the difference in recovered participants in
pharmacological and nonpharmacological control groups, weighted
by sample size. (Color version of figure is available online.)
Fig 6. Box plot showing the difference in recovered adults and
children, classified into nonpharmacological and pharmacolog-
ical control groups, weighted by sample size. (Color version of
figure is available online.)
Fig 4. Box plot showing the difference in recovered participants
between the 4 subgroups in the nonpharmacological studies; number
of cases are given. (Color version of figure is available online.)
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was a 6.9% (significant) difference in favor of children. This
means that, overall, children have higher recovery rates
compared with adults. Children also experienced signifi-
cantly more adverse events than adults: 18.9% (95% CI,17.8-20.0) of the children vs 11.7% (95% CI, 11.4-12.0) of
the adults.
Study Design. When the recovery rates in crossover design
studies were comparedwith parallel group studies, a small but
significant difference was found in recovery between parallel
and crossover studies: 36.9% (95% CI, 36.0-37.7) vs 31.4%
(95% CI, 30.2-32.6), respectively (Fig 7). From the parallel
control groups, 22.4% (95%CI, 21.8-23.0) of the participants
was pain free 2 hours after administration vs 19.7% (95% CI,
18.8-20.7) of the participants in crossover design studies.
TTH vs Migraine. The difference in recovery rates in the
control groups was compared between TTH and migraine
patients. The TTH patients had a mean recovery rate of
34.1% (95% CI, 33.2-34.9) vs 40.7% (95% CI, 39.5-42.0)
of patients diagnosed with migraine, which is a significant
difference. This was still the case when we corrected for the
quality scores and the age of the participants.DISCUSSION
In our review, we found a mean recovery rate of 35.7% in
the control groups; 34.1% of TTH patients improved vs
40.7% of the children and adolescents in migraine studies.
Because there were no adults in the migraine studies, we
corrected for age and found that the difference between TTH
and migraine recovery increased and was still significant. A
ig 7. Box plot showing the difference in recovered participants
lassified into parallel group studies and crossover design
tudies, weighted by sample size. (Color version of figure is
vailable online.)
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s
a,possible explanation for this difference in recovery is the
fact that migraine attacks have a shorter duration than TTH
attacks. Therefore, the proportion of recovered participants
due to natural course may be higher in migraine trials.
Overall, 21.8% of the patients were pain free 2 hours
after medication administration. When we compared our
results with other reviews, we found comparable effects:
Bendtsen et al18 found an average placebo response rate of
30% and a pain-free rate of 9%; Fernandes et al7 found a
46% response rate in the control groups, whereas 21% was
pain free; and Diener et al8 also described similar outcomes
from different studies. All of these studies described results
gathered in migraine trials. We were unable to compare our
results with trials that described the response for “no
treatment” or placebo control groups in TTH patients.
There was a significantly higher recovery rate in the
control groups in pharmacological trials compared with
nonpharmacological trials (38.5% vs 15.0%). Reviews have
shown that active pharmacological treatment is
effective,10,13 whereas the literature on the effectiveness
of active prophylaxis and behavioral treatments is incon-
sistent or lacking.9,11,12,14,15 Participants who received
acute placebo medication recovered significantly more than
participants who received prophylactic placebo medication,
but the difference was small (7%). Diener et al8 also found
that the placebo response in acute migraine medication was
higher than the response in prophylactic trials. A possible
explanation for the difference in placebo response is the factthat, in acute trials, participants have to take the study
medication when they experience complaints, whereas, in
prophylactic trials, they have to take the study medication
on a continuous basis, even if they are symptom free.
In pharmacological trials, where a placebo is often used
as a control, double blinding is possible. In these studies,
patients having the expectation of receiving a real treatment
might explain the higher recovery rates compared with the
nonpharmacological trials. In nonpharmacological trials,
blinding is often not possible.19 In the WLC and attention
placebo groups, significantly more participants recovered
(17.9% and 18.3%) than in the pseudobehavioral groups or
“others” (8.4% and 6.4%). In the group “others,” most
participants received no treatment, nor were they placed on
a waiting list; so they had no perspective of a future
treatment. This and the natural fluctuation of headache
probably might explain the difference in recovery between
this group and the WLC.
We found a small but significant difference in recovery
rates between adults and children in the total study
population after correction for quality score (35.4% vs
37.7%). Children responded better in the pharmacological
trials. This observation is in accordance with other
studies.7,8,20 Based on these studies, we also expected
children to recover more in nonpharmacological trials; but
we were unable to find support for these findings in our data.
After correction, there was no longer a significant difference
between adults and children in the nonpharmacological
trials. The higher recovery rate in children could possibly be
explained by their higher expectations.8 Also, in migraine,
attacks are known to be shorter in childhood. Therefore,
when children in the “no treatment” or placebo control
groups improve, their improvement is more likely a result
of natural course than an effect of the study medication.7,20
The degree of recovery seemed to correspond with the
study design: the recovery rate was significantly lower in
crossover trials than in parallel group trials. This is probably
related to the fact that participants in cross-over trials know
that they are going to receive placebo at a certain time. This
effect has also been described in prior studies.18,21,22Recommendations
In general practice (or family practice) as well as
other health care professions, headache is a common
complaint.1,23,24 In the Netherlands, the standard pharma-
cological treatment according to the general practice
guideline is to start with analgesics like acetaminophen or
nonsteroidal anti-inflammatory drugs in the case of TTH.25
In the case of children with migraine, the first step is a
combination of an analgesic with an antiemetic.1,26
Pharmacological treatment starts when nonpharmacological
treatments like lifestyle changes, relaxation therapy,
cognitive therapy, and reassurance did not work.25 Many
of these prescribed (or over-the-counter) medications,
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adverse events and can cause medication overuse headache.
Considering these risks, we recommend that the prescrip-
tion of medication needs to be carefully considered and
evaluated with each individual patient. Because of our
recovery results in “no treatment” control groups in
pharmacological trials, the question rises whether or not
this way of prescription is always preferable over no
treatment (wait and see) especially in the TTH population.
Our results of the placebo response are not comparable to
“wait and see” in general practice because a part of this
placebo response could be attributed to the expectations of
the participants, who believed that they received an active
treatment. On the other hand, a placebo cannot easily be
prescribed in daily clinical practice.
During our research, we also found studies that
compared behavioral treatment with a pseudobehavioral
treatment. As described before, there was a wide variety of
these control groups. This raises the question whether or
not some of them are plausible for patients, for example, in
the case of studies where patients only had to lie still on a
bed for 10 minutes.16 On the other hand, most “no
treatment” control groups in nonpharmacological studies
had elements of real treatment like attention, information,
and hope for recovery. In the case of pseudobehavioral
treatments, the participants believed they received an active
treatment. Therefore, none of these “no treatment” control
groups were absolute no treatment and were not completely
generalizable to daily practice. The “no treatment” control
groups in future studies should be carefully and precisely
defined because our study shows that “no treatment” is
open to many interpretations.Limitations
Our results may have been influenced by several
shortcomings. First, the different studies used a wide
variety of outcome measures, scales, time intervals, and
chosen end point measures. We tried to group and to
compare the variables as best as possible and preferably
used the ones that were used most frequently. A robust
outcome variable as “pain free” would have been a
desirable outcome measure because of the clear definition.
However, not many studies used pain-free status as
outcome variable. Therefore, mostly “recovery”was chosen
as outcome, based on different rating scales.
Second, all included studies were published before 2005.
When information was missing or when studies showed
inconsistent results, we did not contact the authors for
additional information. This might have led to bias.
However, most trials were published between 1980 and
2000. Therefore, it would be impossible to contact all of
them; and the question remains if this retrieved information
would have led to less bias.Third, the overall study quality was low; only 35.3% of
all the trials had low risk of bias. In general, pharmaco-
logical trials have shown a higher quality score and also a
higher recovery rate in the “no treatment” or placebo
control groups.
Fourth, comparing different control groups, the
number of cases of the outcome variable at interest
varied widely. For instance, when we compared the 4
different subgroups in the nonpharmacological studies,
we found data on recovery for only 37 participants of the
original 133 in the pseudobehavioral group compared
with data of 164 participants of the original 279 in the
WLC group. The number of missing cases varied widely
for the different comparisons. Because of this fact,
looking at the box plots symmetry, one can see that some
of them are well shaped, whereas others are not
symmetrical, although we assumed that they were all
normally distributed. Our results may therefore be biased
as a consequence of the low number of cases in some of
the calculations. Also, because of the nonnormality of the
distributions of the results in some of the subgroups, our
results may not be generalizable to the general population
or the population of adults with migraine. However, our
results considering the pharmacological studies are
comparable to the current literature on migraine. We
were unable to compare our results with literature
concerning placebo response in TTH patients, so further
investigation should be aimed at this particular subgroup.
Fifth, when necessary, we corrected for the confounders
age and quality score because they varied widely
throughout the included trials and might have affected the
outcome. Finally, treatment effects of headache are
complex; thus in future investigations, new models should
be considered.27CONCLUSION
This study showed a relatively high overall recovery rate
in the “no treatment” or placebo control groups (35.7%).
Control groups in pharmacological trials showed a higher
response rate than nonpharmacological trials (38.5% vs
15.0%), and children had a higher recovery rate than adults
in pharmacological trials (45.1% vs 36.5%). Recovery rates
in control groups in acute medication trials seemed to be
higher compared with prophylactic trials (39.6 vs 32.8).
Participants in waiting list and attention placebo control
groups recovered more than those in the other nonpharma-
cological control groups (17.9% and 18.3% vs 8.4% and
6.4%). With all studies combined, participants in control
groups of parallel trials showed a higher recovery rate than
the participants in crossover trials (36.9% vs 30.4%); and
migraine patients recovered more than TTH patients
(40.7% vs 34.1%).
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control groups was large; therefore, the label of “no
treatment” is open to many interpretations.Practical Applications
• The mean recovery rate in the control groups was
35.7%.
• The recovery rate in the control groups varied
substantially between type of intervention
evaluated.
• The recovery rate in pharmacological control
groups is significantly higher compared to the
recovery rate in non-pharmacological control
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